



Amendment to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.


1. (Currently amended) A 2-deoxyglucose conjugate, wherein said conjugate is represented by the formula:




or a pharmaceutically acceptable salt thereof, wherein L is a linker group; and D is selected from the group consisting of BChlPP of the formula



BChlE6 (bacteriochlorin e₆) of the formula



and NIR664 (tricarbocyanine) of the formula



2. (original) The conjugate of claim 1, wherein said linker group, L, is selected from the group consisting of a covalent bond, -NH-, -peptide-, -nucleic acid-, -O-, (CH₂)_r-O-, -NH-CH₂-CH₂-NH-, -NH-CH(COOH)-CH₂-NH-, -NH-CH₂-CH(COOH)-NH-, -NH-CH₂-CH₂-CH₂-NH-, -O-(CH₂)_r-NH-, S-(CH₂)_r-NH-, -S-(CH₂)_r-C(O)-, -NH-CH₂-C(O)-, -O-CH₂-CH₂-O-CH₂-CH₂-O-, -NH-NH-C(O)-CH₂-, -NH-C(CH₂)₂-C(O)-, and -NH-NH-C(O)-(CH₂)_r-C(O)NH-N=, wherein r, in each instance, is from 2-5.

3-24. (cancelled)

25. (Original) A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

26-36. (cancelled)